drugset / Trial / NCT06707532
The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)
RandomizedParallel-groupDouble-blindScreening
Summary
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rocuronium | Other / unclassified | 0.1 mg/kg | Intravenous |
| Comparator | Rocuronium | Other / unclassified | 0.3 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 0.25 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 0.75 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 1.5 mg/kg | Intravenous |
| Comparator | Propofol | Small molecule | 2 mg/kg | Intravenous |